Burden and cost of multiple sclerosis
ECTRIMS Online Library. Kobelt G. 09/13/19; 279550; 288
Gisela Kobelt
Gisela Kobelt
Contributions
Abstract

Abstract: 288

Type: Scientific Session

Abstract Category: Scientific Session 14: Socioeconomic outcomes in MS

G. Kobelt

European Health Economics AB, Stockholm, Sweden

The burden of a disease can be defined in a number of ways, but essentially it is in the eye of the beholder: for people with MS it can mean reduced quality of life through physical suffering, limitations in daily life, loss of work, anxiety and also costs; for patients' relatives it may mean time and effort spent on support, anxiety and costs; for society it means loss of healthy life years, costs and production losses; for the health care budget it is essentially costs. The challenge for burden and cost of illness studies is to be general enough to provide information on most or even all of these aspects.
The presentation will focus primarily on societal aspects that are the consequences of the disease. The data presented were collected to provide basic information on what features of MS cause the major cost burden and how symptoms of the disease affect economic aspects. In addition, they are structured to be used for economic evaluations of new treatments that can change these aspects. Economic evaluation measures cost and outcome, with however a strong focus on outcome and how it changes with interventions, as costs can be adjusted by decision. The data allow thus to investigate what outcomes matter.
Disclosure: The study presented was supported with an independent grant from Biogen.
The author is or has been a consultant, member of advisory boards, study expert, speaker, etc to Biogen, Merck-Serono, Novartis, Roche, Genzyme-Sanofi, Teva in the field of MS.

Abstract: 288

Type: Scientific Session

Abstract Category: Scientific Session 14: Socioeconomic outcomes in MS

G. Kobelt

European Health Economics AB, Stockholm, Sweden

The burden of a disease can be defined in a number of ways, but essentially it is in the eye of the beholder: for people with MS it can mean reduced quality of life through physical suffering, limitations in daily life, loss of work, anxiety and also costs; for patients' relatives it may mean time and effort spent on support, anxiety and costs; for society it means loss of healthy life years, costs and production losses; for the health care budget it is essentially costs. The challenge for burden and cost of illness studies is to be general enough to provide information on most or even all of these aspects.
The presentation will focus primarily on societal aspects that are the consequences of the disease. The data presented were collected to provide basic information on what features of MS cause the major cost burden and how symptoms of the disease affect economic aspects. In addition, they are structured to be used for economic evaluations of new treatments that can change these aspects. Economic evaluation measures cost and outcome, with however a strong focus on outcome and how it changes with interventions, as costs can be adjusted by decision. The data allow thus to investigate what outcomes matter.
Disclosure: The study presented was supported with an independent grant from Biogen.
The author is or has been a consultant, member of advisory boards, study expert, speaker, etc to Biogen, Merck-Serono, Novartis, Roche, Genzyme-Sanofi, Teva in the field of MS.

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies